Teladoc Health (NYSE:TDOC) Stock Price Up 7.7% - Here's Why

Key Points

• Shares were up 7.7% on Friday to about $6.53 on lower-than-average volume, with unusually large call buying (≈28,675 calls) suggesting heightened bullish or speculative interest.
• Q1 results were mixed: Teladoc reported a narrower GAAP loss and a slight revenue beat ($613.8M, -2.5% YoY), but missed EPS (-$0.36 vs. -$0.34) and lowered FY and Q2 EPS guidance, highlighting near-term execution and valuation risk.
• Wall Street sentiment is divided after several target cuts; the consensus rating is a “Hold” with an average target of about $7.47, and the company’s market cap is roughly $1.16 billion.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report)'s share price rose 7.7% during trading on Friday . The company traded as high as $6.42 and last traded at $6.5250. Approximately 2,156,414 shares were traded during trading, a decline of 64% from the average daily volume of 5,917,385 shares. The stock had previously closed at $6.06.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Unusually large call buying — traders bought ~28,675 call options on Friday (about 102% above average), indicating increased bullish positioning or speculative interest that can amplify upside momentum in the stock.
• Positive Sentiment: Narrower Q1 net loss and signs of operating tightening — Teladoc reported a smaller GAAP loss (down to ~$63.8M from ~$93M a year ago) and management emphasized cost discipline and progress toward breakeven, which supports a more constructive investment narrative. How Teladoc’s Narrower Q1 Loss Amid Softer Revenue Has Changed Its Investment Story
• Positive Sentiment: FY revenue guidance skewed to the upside — Teladoc gave full-year revenue guidance range modestly above consensus, suggesting confidence in annual revenue recovery even as quarters may fluctuate; that outlook can be supportive for medium-term valuation. Teladoc Health Reports First Quarter 2026 Results
• Neutral Sentiment: Revenue narrowly beat estimates but remains down year-over-year (~$613.8M, -2.5% YoY) — a mixed signal: beat vs. Street yet continued top-line pressure. Q1 2026 Press Release (Teladoc)
• Neutral Sentiment: Analyst and sector write-ups (Hims & Hers comparison) are exploring relative upside and strategy differences, which may influence sentiment but aren’t direct catalysts. HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?
• Negative Sentiment: EPS missed modestly (reported -$0.36 vs consensus -$0.34) and management lowered EPS guidance for FY and set a Q2 EPS range that implies continued losses, both worse than Street expectations — this raises short-term valuation risk. MarketBeat: Teladoc Earnings
• Negative Sentiment: Q2 revenue guidance came in below consensus, and analysts flagged cash flow and business-model transition concerns on the call — near-term growth headwinds could pressure the stock if execution slips. Teladoc Surprises With Q1 Sales But Stock Drops Q1 Call Highlights

Wall Street Analysts Forecast Growth

TDOC has been the subject of a number of research reports. Oppenheimer decreased their target price on Teladoc Health from $12.00 to $7.00 and set an "outperform" rating for the company in a report on Tuesday, March 3rd. BMO Capital Markets decreased their target price on Teladoc Health from $8.00 to $5.00 and set a "market perform" rating for the company in a report on Thursday, February 26th. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 target price (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Teladoc Health in a report on Friday, March 27th. Finally, Bank of America raised Teladoc Health from a "neutral" rating to a "buy" rating and set a $7.00 target price for the company in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $7.47.

Teladoc Health Price Performance

The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -6.68 and a beta of 2.07. The stock has a fifty day simple moving average of $5.40 and a 200-day simple moving average of $6.46. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.32%. The company had revenue of $613.85 million during the quarter, compared to analyst estimates of $610.87 million. During the same period in the previous year, the firm posted ($0.53) earnings per share. The company's revenue was down 2.5% compared to the same quarter last year. Teladoc Health has set its FY 2026 guidance at -1.050--0.750 EPS and its Q2 2026 guidance at -0.300--0.200 EPS. On average, equities research analysts anticipate that Teladoc Health, Inc. will post -0.89 EPS for the current year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total value of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares of the company's stock, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.70% of the company's stock.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently made changes to their positions in TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Teladoc Health by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider's stock valued at $1,542,000 after buying an additional 5,235 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider's stock valued at $90,000 after buying an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Teladoc Health by 5.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider's stock valued at $3,566,000 after buying an additional 24,124 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Teladoc Health in the first quarter valued at approximately $615,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Teladoc Health in the second quarter valued at approximately $89,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.